(BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted two more abbreviated new drug applications (ANDAs) to the US FDA.
IGI President and CEO Charlie Moore commented “We are excited to announce that we successfully developed and submitted two more ANDAs. Our experienced team of development professionals is focused on our mission, to build a portfolio of topical drug products for IGI.” The development of ANDA products has successfully been integrated into the company’s ongoing contract services business.
- 0
- 1
- 2
- 3
- 4
prev
next
IGI Laboratories Announces 1st Quarter 2012 ResultBUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the first quarter ended March 31, 2012. First Quarter 2012 Highlights vs. 2011 Total revenues of $1.8 million ... Tuesday, 15 May 2012 Continue |
IGI Labs to hold conference call for 1st qtr 2012BUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, will hold a conference call at 4:15 pm ET on Tuesday, May 15, 2012 to discuss 1st quarter 2012 results. The Company invites you to listen to the ... Friday, 4 May 2012 Continue |
IGI Labs to hold conference call for 1st qtr 2012BUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, will hold a conference call at 4:15 pm ET on Tuesday, May 15, 2012 to discuss 1st quarter 2012 results. The Company invites you to listen to the ... Friday, 4 May 2012 Continue |
IGI Labs Announces 4th Qtr 2011 and Year End 2011BUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the fourth quarter and year ended December 31, 2011. Fourth Quarter 2011 Highlights vs. 2010 • Total Revenues of $2.1 million, increase of 21% ... Tuesday, 20 March 2012 Continue |
IGI Labs to hold conference call for 4th qtr 2011BUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, will hold a conference call at 4:30 pm ET on Tuesday, March 20, 2012 to discuss 4th quarter 2011 results. The Company invites you to listen to the ... Monday, 12 March 2012 Continue |
IGI Laboratories Announces the Submission of FifthBUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted an additional abbreviated new drug application (ANDA) to the US FDA, bringing the company’s total number of submissions to five. IGI President and CEO Charlie ... Thursday, 29 December 2011 Continue |
IGI Laboratories Announces the Submission of FifthBUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted an additional abbreviated new drug application (ANDA) to the US FDA, bringing the company’s total number of submissions to five. IGI President and CEO Charlie ... Thursday, 29 December 2011 Continue |
IGI Laboratories and Neostrata Company, Inc. Exten(BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, and NeoStrata Company, Inc., (www.neostrata.com) headquartered in Princeton, NJ, announced a three-year extension to their Turnkey Manufacturing Services agreement. Under the terms of the extension, IGI Laboratories, Inc. (IGI) will continue supplying NeoStrata ... Thursday, 22 December 2011 Continue |
IGI Laboratories and Neostrata Company, Inc. Exten(BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, and NeoStrata Company, Inc., (www.neostrata.com) headquartered in Princeton, NJ, announced a three-year extension to their Turnkey Manufacturing Services agreement. Under the terms of the extension, IGI Laboratories, Inc. (IGI) will continue supplying NeoStrata ... Thursday, 22 December 2011 Continue |
IGI Laboratories, Inc. and Medimetriks PharmaceutiBUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has entered into a long term strategic partnership with Medimetriks Pharmaceuticals, Inc. This strategic partnership designates IGI Laboratories, Inc. (IGI) as the developer and manufacturer of ... Thursday, 8 December 2011 Continue |
IGI Laboratories, Inc. and Medimetriks PharmaceutiBUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has entered into a long term strategic partnership with Medimetriks Pharmaceuticals, Inc. This strategic partnership designates IGI Laboratories, Inc. (IGI) as the developer and manufacturer of ... Thursday, 8 December 2011 Continue |
IGI Laboratories Announces the Submission of Two M(BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted two more abbreviated new drug applications (ANDAs) to the US FDA.IGI President and CEO Charlie Moore commented “We are excited to announce that we successfully developed and ... Friday, 2 December 2011 Continue |
IGI Laboratories Announces the Submission of Two M(BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted two more abbreviated new drug applications (ANDAs) to the US FDA.IGI President and CEO Charlie Moore commented “We are excited to announce that we successfully developed and ... Friday, 2 December 2011 Continue |
IGI Laboratories, Inc. Ranked Number 23 Fastest GrAttributes 133% Percent Revenue Growth to a commitment to excellence. Buena, New Jersey, October 19, 2011 — IGI Laboratories, Inc. today announced it ranked 23rd on Deloitte’s 2011 Greater Philadelphia Fast 50 ranking of the 50 fastest growing technology, media, telecommunications, life sciences and clean technology companies in the Greater Philadelphia ... Wednesday, 9 November 2011 Continue |
IGI LABS TO HOLD CONF. CALL FOR 3rd QUARTER 2011 RBUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, will hold a conference call at 4:30 pm ET on Monday, November 21, 2011 to discuss 3rd quarter 2011 results. The Company invites you to listen to the call by dialing ... Wednesday, 9 November 2011 Continue |
IGI Laboratories Announces the Submission of Two More ANDAs
Management Update Conference Call
sponsored by
Webcast Registration
Date and Time
Tuesday, May 15, 2012 - 4:15 p.m. ET
For call in numbers to the conference,
call please visit the press release page here.